Development of therapy-related myelodysplastic syndrome or secondary AML (tMDS/sAML) is well described and documented in patients undergoing auto-SCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The prognosis of tMDS/sAML is very poor with median survival o6 months. 6 Should concern about myelodysplastic syndrome developing affect the decision of auto-SCT? Intuitively, the answer is yes. However, it is not simple as the OS of the patients is also dependent on the primary disease for which the transplantation is performed. To address this question, we analyzed the OS of patients with lymphoma who had undergone auto-SCT in our institution.
Patients with lymphoma who underwent autologous PBSC transplantation were identified in the Blood and Marrow Transplant Program at Wake Forest University Comprehensive Cancer Center. All patients who underwent transplantation had provided signed informed consent. The current chart review was also approved by the Institutional Review Board.
The clinical data, incidence of tMDS/sAML and survival data were analyzed by Kaplan-Meier plots (log-rank test). Consecutive patients (n ¼ 452) with lymphoma were identified from 1991 to 2006 with 274 males and 178 females, and a median age of 50 years (range: 16-76 years). There were 85 patients with Hodgkin's lymphoma (HL) and 367 with non-Hodgkin's lymphoma (NHL), among which were 132 cases of diffuse large B-cell lymphoma (DLBCL) and 103 cases of follicular/indolent lymphoma (FL). A total of 24 patients (5.3%) developed MDS with a median time of onset of 4.2 years (range: 8 months-7.5 years).
Assuming a prognostic factor, f(mds), that can predict with 100% certainty the occurrence of MDS after transplantation, we analyzed the Kaplan-Meier plots of all cases-HL, DLBCL or FL (Figures 1 and 2 )-using f(mds) equal to 1 or 0 to predict cases that subsequently develop tMDS/sAML or not, respectively.
The survival curves of these different cases are similar to each other. Among all cases of HL and DLBCL, the survival curves of those with and without f(mds) are not statistically different. However, among FL cases, the survival curves of those with and without f(mds) are statistically different (log-rank P ¼ 0.044).
As the patients have to survive long enough to develop tMDS/sAML, their chance of survival tends to be better than those patients who do not develop tMDS/sAML in the initial period after transplantation. However, the survival curves eventually cross over as the prognosis of tMDS/sAML is so poor once diagnosed.
Our analysis is completely hypothetical because it is almost impossible to predict MDS 100%. However, if it were possible to predict, the lack of significant difference in the survival curves among patients with HL and DLBCL suggests that these patients would have a similar chance of survival whether they develop tMDS/sAML or not. Presumably, it is the aggressive nature of HL and DLBCL that will adversely affect survival in a way similar to that of tMDS/sAML. However, the situation is quite different with FL in which those who develop tMDS/sAML have significantly poor survival. One should be more concerned with the possible development of tMDS/sAML in FL. The potential benefit derived from autologous transplantation can easily be offset by the adverse outcome of tMDS/sAML.
Should the concern about myelodysplastic syndrome affect the decision of auto-SCT? On the basis of the analysis of our limited sample, one should not be too concerned about patients with aggressive lymphoma but should be mindful and more cautious about patients with lower grade lymphoma.
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